ReviewJournal of clinical medicine2019
Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Metabolomic profiling and anti-tumor function of canine NK cells in tumor interaction.BMC veterinary research · 2026Article
- CD94 as a novel marker for immunophenotyping of leukemia and lymphoma in dogs.Frontiers in veterinary science · 2025Article
- Development of a deep learning-based 1D convolutional neural network model for cross-species natural killer T cell identification using peripheral blood mononuclear cell single-cell RNA sequencing data.Veterinary world · 2024Article
- Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.Journal for immunotherapy of cancer · 2024Article
- Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma.Veterinary sciences · 2024Article
- Improved characterization and translation of NK cells for canine immunotherapy.Frontiers in veterinary science · 2024Review
- Missing a "Missing Self" Mechanism: Modeling and Detection of Ly49 Expression in Canine NK Cells.ImmunoHorizons · 2023Article
- Vet-OncoNet: Developing a Network of Veterinary Oncology and Reporting a Pioneering Portuguese Experience.Veterinary sciences · 2022Article
- Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.Frontiers in immunology · 2022Article
- There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.Veterinary and comparative oncology · 2021Review
- Comparative Expression Analysis of Innate Immune Markers and Phagocytic Activity in Peripheral Blood of Dogs with Mammary Tumors.Animals : an open access journal from MDPI · 2021Article
- Immunotherapy for Dogs: Still Running Behind Humans.Frontiers in immunology · 2021Review
- Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.Frontiers in veterinary science · 2021Article
- Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.Frontiers in oncology · 2021Review
- Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.Frontiers in immunology · 2021Article
- Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance.Frontiers in veterinary science · 2021Review
- Improving human cancer therapy through the evaluation of pet dogs.Nature reviews. Cancer · 2020Review
- DNA Vaccine Treatment in Dogs Experimentally Infected withJournal of immunology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming. However, barriers have arisen in the effective translation of NK cells to the clinic, in part because of critical species differences between mice and humans. Companion animals, especially dogs, are valuable species for overcoming many of these barriers, as dogs develop spontaneous tumors in the setting of an intact immune system, and the genetic and epigenetic factors that underlie oncogenesis appear to be similar between dogs and humans. Here, we summarize the current state of knowledge for dog NK cells, including cell surface marker phenotype, key NK genes and genetic regulation, similarities and differences of dog NK cells to other mammals, especially human and mouse, expression of canonical inhibitory and activating receptors, ex vivo expansion techniques, and current and future clinical applications. While dog NK cells are not as well described as those in humans and mice, the knowledge of the field is increasing and clinical applications in dogs can potentially advance the field of human NK biology and therapy. Better characterization is needed to truly understand the similarities and differences of dog NK cells with mouse and human. This will allow for the canine model to speed clinical translation of NK immunotherapy studies and overcome key barriers in the optimization of NK cancer immunotherapy, including trafficking, longevity, and maximal in vivo support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.